State Street Corp Acquires 95,051 Shares of AxoGen, Inc. (NASDAQ:AXGN)

State Street Corp lifted its holdings in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 11.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 896,674 shares of the medical equipment provider's stock after buying an additional 95,051 shares during the period. State Street Corp owned about 2.04% of AxoGen worth $12,571,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of AXGN. Divisadero Street Capital Management LP lifted its stake in AxoGen by 587.2% in the 2nd quarter. Divisadero Street Capital Management LP now owns 686,994 shares of the medical equipment provider's stock valued at $4,974,000 after purchasing an additional 587,024 shares during the last quarter. FMR LLC lifted its stake in AxoGen by 743.1% in the 3rd quarter. FMR LLC now owns 178,957 shares of the medical equipment provider's stock valued at $2,509,000 after purchasing an additional 157,730 shares during the last quarter. Rice Hall James & Associates LLC lifted its stake in AxoGen by 26.8% in the 2nd quarter. Rice Hall James & Associates LLC now owns 194,269 shares of the medical equipment provider's stock valued at $1,407,000 after purchasing an additional 41,095 shares during the last quarter. Semanteon Capital Management LP acquired a new stake in AxoGen in the 3rd quarter valued at about $603,000. Finally, Oppenheimer & Co. Inc. acquired a new stake in AxoGen in the 3rd quarter valued at about $156,000. 80.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of AxoGen from a "hold" rating to a "buy" rating in a research note on Tuesday, October 15th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $15.00.

AxoGen Stock Performance

AxoGen stock traded up $0.47 during trading hours on Thursday, hitting $16.73. The company had a trading volume of 502,471 shares, compared to its average volume of 391,877. The firm has a market cap of $736.29 million, a PE ratio of -52.28 and a beta of 1.06. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. AxoGen, Inc. has a one year low of $5.55 and a one year high of $17.23. The firm has a 50-day moving average of $14.12 and a 200 day moving average of $11.98.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.